Literature DB >> 17635073

Reliability of oxidative stress biomarkers in hemodialysis patients: a comparative study.

Simonetta Palleschi1, Sandro De Angelis, Loretta Diana, Barbara Rossi, Vincenza Papa, Giancarlo Severini, Giorgio Splendiani.   

Abstract

BACKGROUND: Oxidative stress (OS) is considered to play a major role in the development of end-stage renal disease (ESRD) complications. However, conflicting and inconsistent data have been reported on OS in ESRD patients. Our aim was to investigate the reliability of the most popular non-enzymatic plasma OS biomarkers in ESRD.
METHODS: Vitamins A (VitA), E and C (VitC), uric acid, plasma antioxidant and ferric-reducing potential (PAP and PRP), thiols (SH), malondialdehyde (MDA) and lipid hydroperoxides (HPO) were determined before and after dialysis in plasma from 33 ESRD patients on hemodialysis, hemodiafiltration or peritoneal dialysis and 20 control subjects.
RESULTS: In ESRD patients, high PRP and normal PAP values were positively correlated with VitC levels. After dialysis, PRP levels decreased, while unchanged PAP levels correlated positively with high VitA and transiently recovered SH values. All patients showed high levels of both MDA and cholesterol-normalized HPO. However, while the former significantly decreased after dialysis, the latter were unaffected by treatment. Paradoxical correlations of MDA with both VitA and HPO were found.
CONCLUSIONS: Plasma PRP and MDA levels may be dramatically affected by both uremia and dialysis; their use in ESRD patients may therefore lead to OS misevaluation and should be avoided. More reliable results can be obtained using physiologically relevant OS functional tests, such as PAP, and early biomarkers of OS damage, such as SH and HPO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635073     DOI: 10.1515/CCLM.2007.266

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Oxidative stress in patients treated with continuous ambulatory peritoneal dialysis (CAPD) and the significant role of vitamin C and E supplementation.

Authors:  Georgios Boudouris; Ioannis I Verginadis; Yannis V Simos; Andreas Zouridakis; Vasilios Ragos; Spyridon Ch Karkabounas; Angelos M Evangelou
Journal:  Int Urol Nephrol       Date:  2012-12-02       Impact factor: 2.370

Review 2.  Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease.

Authors:  Chih-Chien Sung; Yu-Chuan Hsu; Chun-Chi Chen; Yuh-Feng Lin; Chia-Chao Wu
Journal:  Oxid Med Cell Longev       Date:  2013-08-24       Impact factor: 6.543

3.  Using the cytokinesis-block micronucleus cytome assay to evaluate chromosomal DNA damage in chronic renal patients undergoing bicarbonate haemodialysis and haemodiafiltration.

Authors:  M Guido; A Zizza; M R Tumolo; G Stefanelli; M D'Alba; A Idolo; F Bagordo; F Serio; T Grassi; A DE Donno
Journal:  J Prev Med Hyg       Date:  2016-09

4.  Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia.

Authors:  Ingrid Wiswedel; Daniela Peter; Andreas Gardemann; Francesco Carluccio; Hannelore Hampl; Werner Siems
Journal:  Biomark Insights       Date:  2008-05-27

5.  The reliability and predictive ability of a biomarker of oxidative DNA damage on functional outcomes after stroke rehabilitation.

Authors:  Yu-Wei Hsieh; Keh-Chung Lin; Mallikarjuna Korivi; Tsong-Hai Lee; Ching-Yi Wu; Kuen-Yuh Wu
Journal:  Int J Mol Sci       Date:  2014-04-16       Impact factor: 5.923

6.  Vitamins (A, C and E) and oxidative status of hemodialysis patients treated with HFR and HFR-Supra.

Authors:  Simonetta Palleschi; Paolo M Ghezzi; Giuseppe Palladino; Barbara Rossi; Marino Ganadu; Domenica Casu; Maria Cossu; Giovanni Mattana; Antonio Maria Pinna; Bruno Contu; Tonina Ghisu; Alessandro Monni; Luana Gazzanelli; Maria Cristina Mereu; Franco Logias; Mario Passaghe; Alessandro Amore; Piergiorgio Bolasco
Journal:  BMC Nephrol       Date:  2016-08-26       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.